STATegics, Inc. is a biopharmaceutical company in Menlo Park, CA, committed 
to the discovery and development of orally available small molecule modulators 
of cytokine receptors.  The company has identified proprietary small molecules from
two preclinical programs and demonstrated superior properties when compared to 
alternative drugs.  STATegics is also developing screening technologies for efficient 
and rapid identification of small molecules targeting allosteric sites of cytokine receptors, 
i.e. sites that are unique when compared to the binding sites of the natural ligands.  
The company is working closely with leading experts and advisors, and is advancing 
its key programs both internally and through external collaborations.